J. B. Chemicals & Pharmaceuticals (JBCHEPHARM) Fundamentals 2026 — P/E 53.2x, Revenue Analysis | SniperIQ
J. B. Chemicals & Pharmaceuticals (JBCHEPHARM) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹38,677 Crore, trading at ₹2412.25 on the BSE. This SniperIQ fundamentals page covers J. B. Chemicals & Pharmaceuticals's valuation (P/E 53.2x, P/B 9.2x), profitability (net margin 17.1%), revenue (₹4,148 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is J. B. Chemicals & Pharmaceuticals's market cap?
J. B. Chemicals & Pharmaceuticals (JBCHEPHARM) has a market capitalization of approximately ₹38,677 Crore, trading at ₹2412.25 on the BSE. Market cap moves with the live share price.
What is J. B. Chemicals & Pharmaceuticals's P/E ratio?
J. B. Chemicals & Pharmaceuticals's trailing twelve-month P/E ratio is 53.2x, with a price-to-book (P/B) of 9.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is J. B. Chemicals & Pharmaceuticals?
J. B. Chemicals & Pharmaceuticals runs a net profit margin of 17.1%, a gross margin of 62.8%, and an operating margin of 22.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does J. B. Chemicals & Pharmaceuticals generate?
J. B. Chemicals & Pharmaceuticals reported revenue of ₹4,148 Crore for fiscal year 2026, with net income of ₹709 Crore and earnings per share (EPS) of 45.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does J. B. Chemicals & Pharmaceuticals pay a dividend?
J. B. Chemicals & Pharmaceuticals offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is J. B. Chemicals & Pharmaceuticals financially healthy?
J. B. Chemicals & Pharmaceuticals carries a debt-to-equity ratio of 0.00x and a current ratio of 4.92x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is J. B. Chemicals & Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For J. B. Chemicals & Pharmaceuticals (JBCHEPHARM) the key facts are: market cap ₹38,677 Crore, P/E 53.2x, revenue ₹4,148 Crore, 52-week range 1603.05-2509.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track J. B. Chemicals & Pharmaceuticals's full fundamentals live
Get J. B. Chemicals & Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.